Botanix achieves FDA milestone without breaking sweat

Dermatology company Botanix Pharmaceuticals (ASX: BOT) has safely navigated the US Food and Drug Administration (FDA) mid-cycle review with sofpironium bromide.

Botanix’ lead product is in development for the treatment of primary axillary hyperhidrosis, a medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature.

"This is an exciting chapter for Botanix"No significant issues have been identified as a result of the FDA’s review. This includes no major clinical safety issues, no risk management issues, or advisory board requirements.